SLS shorts ease but borrow market stays tight ahead of November print

SELLAS Life Sciences heads into its November 12 earnings release with one of the most heavily shorted floats in small-cap biotech, a borrow market that has tightened sharply this week, and options traders who have turned notably more bullish over the past fortnight.

Short interest at 37.9% of the free float is the headline number, and it remains extraordinary by any measure. That said, the direction has shifted. Bears have trimmed positions over the past month, with short interest down roughly 6% from its late-September peak of around 59.6 million shares to 54 million now. The FINRA fortnightly settlement figure puts days-to-cover at nearly 12, which means any forced unwind would take the better part of three trading weeks at normal volumes. Shorts have retreated, but they have not departed.

The borrow market tells a more nuanced story. Availability has tightened to just 5.8%, meaning there are fewer than six shares available for every hundred already borrowed, and the trend this week has been toward further tightening after touching a near-fully-squeezed reading of 0.5% on October 13. Cost to borrow has eased meaningfully over the month, falling from above 10% to 7.3% now, suggesting the acute squeeze pressure of mid-October has passed. Still, availability at sub-6% keeps the borrow fragile. The ORTEX short score sits at 82.6, ranking in the 2nd percentile for short-score rank and the 5th percentile for availability rank, placing SLS among the most short-stressed names in the universe.

Options positioning has flipped dramatically since mid-October, and that shift is the most interesting development this week. The put/call ratio has collapsed from above 0.52 in early October to just 0.29 now, more than 1.3 standard deviations below its 20-day average of 0.42. Calls are heavily dominating new options flow. The 52-week low on the PCR is 0.014, so there is room to run further, but the speed and completeness of the rotation from defensive to speculative positioning over two weeks is striking. That shift coincides almost exactly with the stock's 7.3% single-day gain on October 27 and a 1.6% gain on the week to $12.17.

The Street has been quiet on SLS for some time. The most recent analyst action in the data is Maxim Group raising its target to $10 in March 2026, well below the current price of $12.17. A mean consensus target of $32.50 appears in the data but dates to August 2026, and coverage here is thin enough that a single optimistic target can skew the average materially. The valuation is pre-revenue biotech: a negative P/E and negative earnings yield, with the stock trading almost entirely on clinical and regulatory optionality. The EPS surprise factor ranks at the 69th percentile, which is respectable, and the stock scores at the sector median on the broader factor composite.

Institutional ownership is worth a glance. BlackRock filed a Schedule 13G amendment on October 27, the same day as the latest data, lifting its disclosed stake to 7.9% from 6.8%. State Street holds 7.0% and Vanguard Capital Management 5.2%. All three are index and passive-style holders, and no Schedule 13D activist is on the register. The Anson Funds position, last disclosed at 4.9% in February, has dropped below the 5% filing threshold since then, a reminder that these disclosures are point-in-time snapshots and silent exits happen. Retail attention, measured by Wikipedia page views against SLS's own 90-day history, is running roughly 1.7 standard deviations below its norm, so the buying pressure this week does not appear to be driven by a fresh wave of retail interest.

With earnings on November 12, just 15 days away, the question is whether the combination of retreating short interest, tightening availability, and a sharp rotation toward calls reflects genuine conviction or simply a short-term position unwind ahead of a binary clinical event. That distinction will be clearest in how availability moves over the next week and whether the PCR holds below its 20-day average into the print.